Overview

Pharmacotherapy, as a means of treating drug addiction in combination with other treatment modalities, has received too little attention from the research community, the pharmaceutical industry, public health officials, and the federal government. Medications to combat drug addiction could have an enormous impact on the medical consequences and socioeconomic problems associated with drug abuse, both for drug-dependent individuals and for American society as a whole. This book examines the current environment for and obstacles to the development of anti-addiction medications, specifically those for treating opiate and cocaine addictions, and proposes incentives for the pharmaceutical industry that would help overcome those obstacles and accelerate the development of anti-addiction medications. Table of Contents Front Matter Executive Summary 1 Introduction 2 Overview of the State of Scientific Knowledge Concerning Drug Addiction 3 Assessment of the Medications Development Division 4 Treatment Setting and Effectiveness 5 Treatment Financing and Trends in Health Insurance 6 Training and Education 7 Federal Laws and Regulations 8 State Laws and Regulations 9 Market Obstacles and Creating Incentives Appendix A: Acknowledgments Appendix B: Organization and Mission Statements of NIDA's Medications Development Division and Its Branches Appendix C: Diagnostic Criteria for Psychoactive Substance Dependence Appendix D: Survey of Pharmaceutical Companies Appendix E: Model Federal Programs in Pharmaceutical R&D Appendix F: Workshop Agenda and Participants Appendix G: Health Care Reform Legislation Appendix H: Acronyms

Full Product Details

Author:   Institute of Medicine ,  Committee to Study Medication Development and Research at the National Institute on Drug Abuse ,  Laurence E. Earley ,  Catharyn T. Liverman
Publisher:   National Academies Press
Imprint:   National Academies Press
Dimensions:   Width: 15.20cm , Height: 1.80cm , Length: 22.90cm
Weight:   0.440kg
ISBN:  

9780309052443

ISBN 10:   0309052440
Pages:   272
Publication Date:   20 February 1995
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Active
Availability:   Out of stock  
The supplier is temporarily out of stock of this item. It will be ordered for you on backorder and shipped when it becomes available.

Table of Contents

1 Front Matter; 2 Executive Summary; 3 1 Introduction; 4 2 Overview of the State of Scientific Knowledge Concerning Drug Addiction; 5 3 Assessment of the Medications Development Division; 6 4 Treatment Setting and Effectiveness; 7 5 Treatment Financing and Trends in Health Insurance; 8 6 Training and Education; 9 7 Federal Laws and Regulations; 10 8 State Laws and Regulations; 11 9 Market Obstacles and Creating Incentives; 12 Appendix A: Acknowledgments; 13 Appendix B: Organization and Mission Statements of NIDA's Medications Development Division and Its Branches; 14 Appendix C: Diagnostic Criteria for Psychoactive Substance Dependence; 15 Appendix D: Survey of Pharmaceutical Companies; 16 Appendix E: Model Federal Programs in Pharmaceutical R&D; 17 Appendix F: Workshop Agenda and Participants; 18 Appendix G: Health Care Reform Legislation; 19 Appendix H: Acronyms

Reviews

Author Information

Carolyn E. Fulco, Catharyn T. Liverman, and Laurence E. Earley, Editors; Committee to Study Medication Development and Research at the National Institute on Drug Abuse, Institute of Medicine

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions